FDA Approves Mounjaro to Cut Heart Risk in Type 2 Diabetes
LLY sits 66% above its 52-week low of $712.05.
Summary
The FDA approved Mounjaro (tirzepatide) to reduce major adverse cardiovascular events in adults with type 2 diabetes at high risk. This is the first GIP/GLP-1 receptor agonist cleared for this indication, expanding the drug's label beyond glucose control and weight loss. The approval is based on SURPASS-CVOT, a 13,000-patient trial showing non-inferiority to Trulicity with an 8% lower MACE-3 rate (HR 0.92). Mounjaro is already the #1 prescribed branded type 2 diabetes medicine in the U.S., and this label expansion addresses the leading cause of death in that population. The news follows Lilly's Q2 report showing 48% revenue growth driven by Mounjaro and Zepbound, reinforcing the franchise's momentum.
At the time of this announcement, LLY was trading at $1,180.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $712.05 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.